The American Journal of Medicine
Volume 123, Issue 11 , Pages 1001-1006 , November 2010

Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression

  • Samy Suissa, PhD

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • Department of Epidemiology and Biostatistics and Department of Medicine, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Samy Suissa, PhD, Centre for Clinical Epidemiology, Jewish General Hospital, 3755 Cote Ste-Catherine, Montreal, Québec H3T 1E2, Canada
    • ,
  • Abbas Kezouh, PhD

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Pierre Ernst, MD, MSc

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • Department of Epidemiology and Biostatistics and Department of Medicine, McGill University, Montreal, Quebec, Canada

  • Image Result

    Adjusted rate ratio of diabetes incidence associated with inhaled corticosteroid use, as a function of the current dose converted to fluticasone equivalents (in μg), along with the corresponding 95% c

    Adjusted rate ratio of diabetes incidence associated with inhaled corticosteroid use, as a function of the current dose converted to fluticasone equivalents (in μg), along with the corresponding 95% confidence limits for the fitted dose-response curve.

 Funding: This research was funded by grants from the Canadian Institutes of Health Research, Boehringer-Ingelheim GmbH, and the Canadian Foundation for Innovation. The sponsors had no role in the design and conduct of the study, including data collection, management, analysis, interpretation, or in the preparation of the manuscript.

 Conflict of Interest: Samy Suissa has received speaker fees or has served on advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, and Pfizer. Pierre Ernst has received speaker fees or has served on advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst Canada, Novartis, and Nycomed.

 Authorship: All authors participated in the preparation of the manuscript.

PII: S0002-9343(10)00648-0

doi: 10.1016/j.amjmed.2010.06.019

The American Journal of Medicine
Volume 123, Issue 11 , Pages 1001-1006 , November 2010

Article Tools

* Image Usage & Resolution